Literature DB >> 6338199

Phagocytosis of Plasmodium falciparum-parasitized erythrocytes by human polymorphonuclear leukocytes.

A Celada, A Cruchaud, L H Perrin.   

Abstract

Polymorphonuclear leukocytes (PMN) from normal blood donors phagocytosed P. falciparum-infected red blood cells (IRBC) to a greater extent than normal RBC under in vitro culture condition. The phagocytic activity of PMN was greatly increased by the addition of sera from individuals living in areas endemic for malaria (immune sera) but not by sera from individuals recovering from a first acute P. falciparum infection. The enhancement of the phagocytic activity was associated with the purified IgG fraction of immune sera and was lost after absorption of IgG on protein A sepharose column of preincubation of the immune sera with IRBC. These experiments suggest that opsonisation of IRBC and their subsequent phagocytosis may be one of the mechanisms involved in the clearance of P. falciparum infection in individuals living in areas endemic for malaria.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338199

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  26 in total

1.  Enhancement of neutrophil-mediated killing of Plasmodium falciparum asexual blood forms by fatty acids: importance of fatty acid structure.

Authors:  L M Kumaratilake; A Ferrante; B S Robinson; T Jaeger; A Poulos
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

Review 2.  Effects of anti-infectious agents on polymorphonuclear neutrophils.

Authors:  M T Labro; J el Benna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

3.  Experimental infection of immunomodulated NOD/LtSz-SCID mice as a new model for Plasmodium falciparum erythrocytic stages.

Authors:  Alicia Moreno Sabater; Marta Moreno; Francisco Javier Moreno; Cesar Eguiluz; Nico van Rooijen; Agustin Benito
Journal:  Parasitol Res       Date:  2004-12-10       Impact factor: 2.289

Review 4.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

5.  Characterization of protective epitopes in a highly conserved Plasmodium falciparum antigenic protein containing repeats of acidic and basic residues.

Authors:  P Sharma; A Kumar; B Singh; A Bharadwaj; V N Sailaja; T Adak; A Kushwaha; P Malhotra; V S Chauhan
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

6.  Oxidative stress and protective mechanisms in erythrocytes in relation to Plasmodium vinckei load.

Authors:  R Stocker; N H Hunt; G D Buffinton; M J Weidemann; P H Lewis-Hughes; I A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

7.  Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.

Authors:  M T Labro; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

8.  Production of luminol-reactive oxygen radicals during Plasmodium vinckei infection.

Authors:  R Stocker; N H Hunt; I A Clark; M J Weidemann
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

9.  Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies.

Authors:  Charlotte Joos; Laurence Marrama; Hannah E J Polson; Sandra Corre; Antoine-Marie Diatta; Babacar Diouf; Jean-François Trape; Adama Tall; Shirley Longacre; Ronald Perraut
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

10.  Effective and cheap removal of leukocytes and platelets from Plasmodium vivax infected blood.

Authors:  Kanlaya Sriprawat; Supaporn Kaewpongsri; Rossarin Suwanarusk; Mara L Leimanis; Usa Lek-Uthai; Aung Pyae Phyo; Georges Snounou; Bruce Russell; Laurent Renia; François Nosten
Journal:  Malar J       Date:  2009-06-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.